Company intelligence / Profile preview

Airmid Inc.

Redwood City, California, United States

Ownership: Private
Development stage: Other

Overview

Developed novel Kv1.3 potassium channel blockers derived from Caribbean sea anemone venom for autoimmune diseases; assets acquired by Kineta in 2009 with planned IND filing for clinical trials in 2010.

Therapeutic areas: EndocrinologyImmunologyNeurologyDermatology
Modalities: Peptides
Industry: Biotech

Partnerships

Kineta (asset acquisition)Circassia (asset licensing)

Beyond the preview

Go deeper on Airmid Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Airmid Inc..

Explore the full profile